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Background: The Sarcoma Policy Checklist was created by a multidisciplinary expert group to provide policymakers
with priority areas to improve care for sarcoma patients.
Main body: This paper draws on this research, by looking more closely at how France, Germany, Italy, Spain,
Sweden and the United Kingdom are addressing each of these priority areas. It aims to highlight key gaps in
research, policy and practice, as well as ongoing initiatives that may impact the future care of sarcoma patients in
different European countries. A pragmatic review of the published and web-based literature was undertaken.
Telephone interviews were conducted in each country with clinical and patient experts to substantiate findings.
Research findings were discussed within the expert group and developed into five core policy recommendations.
The five identified priority areas were: the development of designated and accredited centres of reference; more
professional training; multidisciplinary care; greater incentives for research and innovation; and more rapid access to
effective treatments. Most of the countries studied have ongoing initiatives addressing many of these priorities;
however, many are in early stages of development, or require additional funding and resources.
Conclusion: Gaps in access to quality care are particularly concerning in many of Europe’s lower-resourced
countries. Equitable access to information, clinical trials, innovative treatments and quality specialist care should be
available to all sarcoma patients. Achieving this across Europe will require close collaboration between all
stakeholders at both the national and European level.
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Care pathwaysBackground
What are sarcomas?
Sarcomas are a family of rare cancers with a combined in-
cidence of six people per 100,000 population, with 28,000
new cases each year in Europe [1]. They develop in the
connective tissues and bones, and can occur anywhere in
the body, at any age [1]. There are more than 50 subtypes
of soft tissue sarcoma (STS) alone, each with unique clin-
ical, prognostic and treatment characteristics [1, 2].
Because of this heterogeneity, sarcoma epitomises
many of the challenges encountered with rare cancers.* Correspondence: Suzanne@hpolicy.com
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about their condition, specialised care centres, appropri-
ate courses of care, and ongoing clinical trials [3]. The
heterogeneity of sarcoma also complicates research ef-
forts: recruiting sufficient numbers of patients to large
clinical trials is often impossible, epidemiological data
are scarce and the evidence base to guide clinical prac-
tice is inadequate [1, 4, 5].
Sarcoma patients report some of the poorest experi-
ences of any cancer type [3]. Lack of professional experi-
ence in diagnosing or treating sarcoma is a critical issue,
and may lead to delays and errors in diagnosis and treat-
ment. In one study, 27% of all patients with sarcoma had
been told by their general practitioner that theirle is distributed under the terms of the Creative Commons Attribution 4.0
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ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Kasper et al. BMC Cancer  (2018) 18:424 Page 2 of 8symptoms were not serious, or had been initially treated
for something other than sarcoma [3]. Referral pathways
are often not clearly defined. Access to appropriate care
also varies considerably both between and within coun-
tries. Some treatments are not reimbursed, leaving pa-
tients to pay for treatments out-of-pocket. Many patients
may have to travel great distances to receive appropriate
care [4].The policy landscape
In the past few years, many stakeholders have raised
awareness of the need to improve the patient experience
for patients with rare cancers [4, 5]. Sarcoma has been a
central focus of these efforts, with publications by the
European CanCer Organisation (ECCO) outlining a list
of essential requirements for quality care in STS in
adults and bone sarcoma [6]; a paper on patient path-
ways by Sarcoma PAtients EuroNet (SPAEN) defining
patient-driven recommendations for sarcoma care [7];
and the creation of a European Reference Network
(ERN) on rare adult cancers (EURACAN) including a
domain for adult sarcomas [8].The sarcoma policy checklist
Building on these initiatives, the Sarcoma Policy Check-
list [9] was created and launched at the European
Parliament by a multi-stakeholder group in February
2017. The Checklist aims to provide policymakers with
priority areas where the greatest needs exist to improve
care for sarcoma patients.
This paper draws on research done to build the
Sarcoma Policy Checklist, and looks more closely at how
six Western European countries (France, Germany, Italy,
Spain, Sweden and the United Kingdom (UK)) are ad-
dressing each of the recommendations. Drawing from
the experience in these countries, the paper highlights
key gaps in research, policy and practice, as well as im-
portant developments that may impact future policy and
practice across Europe – recognising that challenges will
differ from one country to another, particularly in lesser-
resourced countries in Europe.
A review of the published and web-based literature on
sarcoma and rare cancers was undertaken, using standard
search terms, which were translated into French, German,
Italian and Spanish to enable local language searches in
relevant countries. Local language searches in Swedish
were deemed unnecessary given that most of the literature
is available in English. Telephone interviews were con-
ducted in each country with local clinical and patient ex-
perts who are members of the expert group of the
Sarcoma Policy Checklist. These helped fill gaps in infor-
mation and obtain an up-to-date representation of the
current situation in each country.Recommendations of the sarcoma policy checklist
Research findings were discussed at several stages within
the expert group, to ensure consensus in recommenda-
tions. The expert group agreed on five key areas where
policymakers should focus efforts to improve care for
sarcoma patients (the Sarcoma Policy Checklist) and is-
sued recommendations for each of these areas. The
Checklist was launched at the European Parliament in
February 2017. Recommendations are presented in
Table 1.
Results
Research findings are summarised below based on data
from France, Germany, Italy, Spain, Sweden and the UK.
This section aims to outline how well each country is
doing in meeting recommendations of the Sarcoma
Policy Checklist, focusing on some of the most salient
issues discussed during expert interviews and identified
in our review of the literature.
Specialist sarcoma care
Centres of reference for the specialised management of
sarcomas exist in all six countries, but they are not al-
ways formally designated by explicit quality criteria, nor
formally recognised by national bodies. The establish-
ment of EURACAN has required countries to nominate
centres of reference to participate based on set criteria,
formalising the designation of centres for the first time
in many countries. In Spain, for example, the Ministry of
Health recently endorsed five national sarcoma reference
centres to take part in EURACAN [10]. In Germany,
two centres – Essen and Mannheim – cover the sarcoma
domain within EURACAN. This situation may vary con-
siderably between countries however.
France has an advanced network that connects all clin-
ical and pathological reference centres for sarcoma. There
are two clinical networks: French Clinical Reference Net-
work for soft tissue and visceral sarcomas (NetSarc) and
French Reference Network for bone sarcoma and rare
bone tumours (ResOs) for the medical oncology part
[11, 12] as well as a Sarcoma Pathological Reference
Network (RRePS), which enables a second expert
pathological review for all STS cases to confirm diag-
nosis [12, 13]. However, a particular issue in France is
that the accreditation of reference centres is based on
a centre’s expertise in oncology, not surgery. There-
fore, the quality of sarcoma surgery varies consider-
ably among centres. This is not necessarily the case
in other countries – for example, quality standards in
the UK are based primarily on a centre’s surgical
expertise.
Even if reference centres are initially designated based
on their adherence to specific criteria, their performance
over time, in terms of meeting quality standards for
Table 1 The Sarcoma Policy Checklist recommendations, published in February 2017
Recommendations What is needed in each country?
i. Each country should have at least one designated and
accredited centre of reference for sarcoma
• At least one national centre of reference, or a clear link to a centre
of reference in another country
• National accreditation processes that designate centres of reference using
specific quality standards
• Regular evaluation of centres of reference against these standards to ensure
continuous quality of care
ii. All healthcare professionals involved in sarcoma care should
have access to specialised training
• Training on rare cancers included in the general medical curriculum
• Specialised training programmes on sarcoma for all healthcare professionals
involved in the sarcoma multidisciplinary care team
• National referral protocols for suspected sarcoma patients, which advise
non-specialists of ‘red flag’ symptoms and when to refer patients to centres
of reference
iii. Sarcoma patients should receive multidisciplinary care delivered
by a specialised sarcoma team
• All sarcoma patients treated by multidisciplinary teams (MDTs) according to
a clear care pathway
• A clear definition of the minimum composition of a MDT
• National guidelines for the treatment of all sarcomas (children and adults)
• A dedicated key health worker and a personalised care plan for each
patient
iv. There should be greater incentives for research and innovation
in sarcoma care
• Incentives for public–private partnerships
• National and international research collaborations for sarcoma
• A national sarcoma registry with a standardised dataset to allow
comparable real-world data collection across centres of reference
v. Sarcoma patients should have more rapid access to effective
treatments
• Alignment between regulatory and reimbursement/HTA agencies on
evidentiary requirements for sarcoma treatments
• Special regulatory and access pathways for rare cancers
• Involvement of sarcoma patients or their representatives in health
technology assessment (HTA) and other access pathways
• Publicly available national and international clinical trial portals listing
all ongoing clinical trials in sarcoma
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of care, still needs to be regularly monitored [4]. Sweden
has a particularly sophisticated monitoring of quality of
sarcoma care through its cancer registry for extremity
and trunk wall sarcoma [14]. In some countries, such as
Italy, there are ongoing efforts by professional societies
to clarify quality standards for specific aspects of care (e.g.
surgery). In Germany, a formal certification process for
reference centres for STS is currently being developed by
the German Cancer Society (DKG).
Professional training
In all six countries studied, there is no formal training
on rare cancers (including sarcoma) within the general
medical curriculum. Training on rare cancers is also not
part of the formal training of oncologists in most coun-
tries, although there are ongoing efforts to change this,
for example in France and Italy.
Specialist training programmes have particularly fo-
cused on surgery at the European level. For example,
there is the European School of Soft Tissue Sarcoma led
by the European Society of Surgical Oncology (ESSO)
[15] and the eSurge programme led by hospitals in both
France and Italy [16].
Other efforts exist which target non-specialists to en-
courage them to quickly refer patients to appropriate
specialists and reference centres. For example, the ‘Onthe ball’ public awareness campaign led by Sarcoma UK
(a patient-led charity) aims to raise awareness among
general practitioners (GPs) of the ‘red flag’ symptoms of
sarcoma, and encourage GPs to refer any suspected sar-
coma case directly to specialist centres quickly [17].
Many patient organisations have called for the estab-
lishment of clear referral pathways to improve access to
expert diagnosis and treatment for sarcoma [7]. Simple
referral guidelines, like those for STS in Sweden (which
recommend referral to reference centres before initial
surgery is performed) have been shown to improve refer-
ral rates, reduce costs associated with local recurrence
and result in better surgical results and overall patient
outcomes [18, 19]. Of patients with deep sarcoma in
Sweden, 80% are referred to a regional reference centre
before biopsy [20].
Clear referral pathways may help improve the ac-
curacy of diagnosis in sarcoma, which remains an
area for improvement. Data from Germany, for ex-
ample, suggest that the error rate of primary diagno-
sis is over 60% among non-specialised pathology
departments [21], while in France over 45% of first
histological diagnoses were modified after a second
reading in the French reference networks and possibly
resulted in an alternative treatment course [22]. Simi-
lar results were found in other regions in France and
Italy [23].
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Most national guidelines, as well as the recent ECCO
and SPAEN recommendations [6, 7], recognise that the
organisation of sarcoma care in multidisciplinary teams
(MDTs) is key to providing high-quality care. This is also
a criterion for reference centres to be considered for in-
clusion into EURACAN.
The networking of centres within both national net-
works (e.g. NetSarc) and EURACAN may provide the
necessary basis for multidisciplinary care practices to de-
velop. For example, in the UK, a National Ewing Sar-
coma Multidisciplinary Team (NEMDT) advisory group
meets regularly and brings together experts from around
the UK to discuss patient treatment plans and best prac-
tice, and to find ways to optimise the patient pathway to
improve survival rates for Ewing sarcoma patients [24].
However, the implementation of an MDT approach re-
mains uneven between individual centres. Many centres
do not have sufficient resources to implement a system-
atic MDT approach for sarcoma care, and appropriately
trained personnel representing each required specialty
are not always available. Moreover, the composition of a
specialist sarcoma MDT is often not clearly defined.
It is also critical for MDTs to include primary and
community-based providers as well as professionals in
hospitals or centres of reference, to ensure high quality
of diagnosis and care across the entire care pathway [6].
Incentives for research and innovation
Across all countries, there remains a need for more basic
and translational research on sarcoma – and funding to
achieve this. Also, clearer regulatory guidance is needed
to encourage the establishment of public–private part-
nerships to drive research in sarcomas; for example, on
the appropriate interaction between academia and in-
dustry in these collaborations.
There are, however, several important ongoing re-
search initiatives on sarcoma. Individual countries have
led focused research efforts in different areas. In 2013,
France had 142 started or ongoing translational studies
on rare cancers, 30% of them in the sarcoma networks
(NetSarc, RRePS and ResOs), and 70 translational stud-
ies completed, 49% of them in the sarcoma networks
[13]. In the UK, Sarcoma UK published a survey of sar-
coma patients in 2015, which has provided important in-
sights into patient experiences [3]. The charity has also
made a strategic commitment to fund £3 million in sci-
entific research by 2020 [25]. In Spain, research is taking
place on very rare and ultra-rare sarcomas to determine
their burden and improve treatment pathways.
As has been mentioned previously, recruiting sufficient
numbers of patients into sarcoma clinical trials remains
an ongoing challenge due to the small number of pa-
tients with each specific type of sarcoma [3–5]. Real-world data pooled from multiple centres as well as
established registries at national and international level
are therefore critical to gather sufficient evidence of how
treatments work in practice, and guide quality improve-
ment efforts. In Sweden, the National Sarcoma Quality
Registry (INCA), which collects sarcoma patient data
from all regions, provides an interesting opportunity for
real-world data analyses. Discussions are also underway
to try to link Swedish sarcoma patient data with data
from other Nordic countries, as they all follow a similar
data collection template. The development of
EURACAN is also likely to play an important role in en-
couraging the collection of comparable real-world data
across different centres. Efforts to develop a standardised
data set for the collection of hospitalisation data are
already in place.Access to treatment and care
Access to appropriate treatment and care is a critical
concern for patients with sarcoma, and rare cancers
more generally. Patient groups are leading efforts in
many countries to try to reduce existing disparities in
access to treatments [7]. If treatments are not reim-
bursed, patients and their families may have to pay for
them out-of-pocket, causing a considerable financial
burden.
Differences in evidentiary requirements between regu-
latory authorities (for license approval) and Health Tech-
nology Assessment (HTA) or reimbursement bodies (for
funding) remain a critical issue for patients’ access to
treatment. For example, the European Medicines Agency
is increasingly allowing flexibility in drug regulatory
pathways for orphan drugs and treatments that address
clear unmet needs in given patient populations, such as
sarcoma. Smaller trials and adaptive trial designs should
be given due consideration for rare cancers, as well as
accelerated review, conditional marketing authorisation
and adaptive licensing [26–28].
This flexibility, however, is not necessarily matched by
reimbursement and HTA agencies in most countries
[27]. In theory, special regulatory pathways applicable to
orphan drugs apply to sarcoma treatments. However,
countries do not have consistent approaches to evaluat-
ing orphan drugs – creating uncertainty about the level
of evidence needed to obtain regulatory approval. This
situation often leads to long delays, or even denial of ac-
cess to patients [4, 27]. Decentralisation of reimburse-
ment and funding decisions to the regional or local level
also contributes to significant inequalities in access to
new treatments for patients in many countries. Early ac-
cess or compassionate use programmes often exist; how-
ever, they have not necessarily been applied to sarcoma,
with some notable exceptions such as the UK.
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and their representatives is their lack of involvement in
reimbursement and funding decisions – for example, in
helping to determine what constitutes ‘meaningful bene-
fit’ from a patient perspective in funding and reimburse-
ment decisions.
Finally, awareness and participation in sarcoma clinical
trials remains inadequate – especially considering that
clinical trials are often the only way patients may access
potentially innovative treatments. Evidence suggests that
sarcoma patients are often not aware of centres of excel-
lence nor of ongoing clinical trials – and physicians may
not be aware of existing clinical trials either [3, 5]. For
example, the National Sarcoma Survey (2015) in the UK
found that the majority of patients (67%) were not asked
whether they wanted to take part in a clinical trial and,
if they were, uptake was low (22% participation) [3].
Discussion
It is important to mention that this paper is based on
findings from six relatively wealthy European countries.
The situation may be very different in some of Europe’s
lower-income countries, where lack of available expertise
and low levels of resources often result in limited access
to quality care for many patients. More extensive re-
search is required to understand the situation in lower-
income countries in Europe.
In the six countries studied, there are numerous prom-
ising developments in sarcoma; however, many gaps re-
main. Efforts to improve access to quality sarcoma care
and subsequent patient outcomes are still needed, as in-
consistent availability of specialist expertise and appro-
priate referral patterns often result in misdiagnosis and
inappropriate treatment for many patients. Strengthen-
ing cross-border healthcare initiatives may help, but
ideally, every country should have at least one national
reference centre for rare cancers with links to more
established reference centres in another country.
European organisations may also play an important role
in building expertise by actively facilitating mentoring,
exchange and support programmes to transfer know-
ledge and practice between countries [7].
Even with one centre of reference in each country and
cross-border links between centres, lack of access to
quality care may persist within a country. Access will
often depend on the existence of suitable transport links.
For example, access to a centralised sarcoma reference
centre from every part of the country may be achievable
in a country with radial transport links, but for countries
with varied shape, and distant regions, regional centres
for routine treatment would be preferable. That being
said, rarer forms of sarcoma would still need to be
treated centrally to retain access to true expertise. This
may apply, for example, to retroperitoneal sarcomas orcomplex amputations in the pelvic or shoulder regions.
A number of solutions may be envisaged to help im-
prove equity in access to high-quality specialist care
across a country, including harmonizing quality criteria
for sarcoma reference centres, producing a national
treatment strategy and clinical trials portal. Where a
centre may lack expertise, technology may also help ad-
dress knowledge gaps, such as through e-consultations.
The growth of IT systems providing decision support
software may also allow for more evidence-based deci-
sions even in smaller or less-resourced MDTs.
The certification process of ‘specialist’ sarcoma centres
remains a critical issue. While the ideal is for centres to
have formal designation with explicit quality criteria and
regular quality reviews, this is not usually the case, as
mentioned in the paper. The absence of explicit quality
criteria is not limited to the field of rare cancers. Self-
certification with peer-review would be possible if gov-
ernments regulated specialised treatment centres, but
they generally do not. The role of the ERNs and guide-
lines in achieving greater harmonisation of quality cri-
teria across designated sarcoma specialist centres
remains to be seen.
As has been mentioned previously, the existence of a
MDT approach is one of the criteria for centres to be-
come part of the ERN for sarcoma. However, it is im-
portant to recognise that consistent implementation of
MDTs remains a challenge, as sometimes even specialist
sarcoma centres are focused on one aspect of treatment
(e.g. surgery) and may lack other specialists to contribute
to a comprehensive MDT. Virtual MDTs linking differ-
ent specialists across centres, again with the help of
technology and IT, may offer a potential solution and
are being explore in a number of countries, as well as in
cross-border care networks. However, it is important to
note that having a full MDT at a centralised specialised
sarcoma centre is the preference, and technology can act
as a tool to facilitate communications between special-
ists – but not to replace specialists.
Inequities in access result in delays or denial of in-
novative treatments for patients, effectively limiting their
treatment options. Better alignment between evidentiary
requirements for regulatory and HTA/access pathways
may help reduce delays in access to new treatments for
patients.
Low participation in clinical trials remains an import-
ant issue for sarcoma patients – often due to low patient
awareness of ongoing studies. More patient involvement
in clinical trial design is needed to help guide research
efforts. Direct patient input into HTA and reimburse-
ment decisions may help ensure value frameworks are
closely aligned with patient priorities.
Greater investment in basic, epidemiological, clinical,
outcomes and translational research is still needed in
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tres and high-quality registries, will be vital to provide
evidence of how effective different interventions are in
practice, and guide quality improvement and research ef-
forts as a result. Yet hurdles such as lack of data stand-
ardisation need to be overcome before the potential of
real-world data can be realised.
Looking beyond national solutions, several pan-European
efforts deserve mention and are outlined in Table 2. It is
also important to recognise the role of European initiatives
aimed at rare cancers more generally.
For example, the European Commission-funded RAR-
ECARE project, which later evolved into RARECARENet
[29], has provided important epidemiological insights
into rare cancers [1, 30]. EURACAN, mentioned previ-
ously, may significantly improve the quality of sarcoma
diagnosis, care, research, and access to clinical trials [8, 31],
as well as facilitating cross-border care [32]. However, ad-
equate funding for reference centres still needs to be
secured [33].
The Joint Action for Rare Cancers (JARC), of the third
EU Health Programme 2014–2020, is also important. It
is a collaboration between 18 member states that aims
to integrate the needs for rare cancers into national can-
cer plans by advancing quality of care and research on
rare cancers [34, 35]. The JARC provides direct supportTable 2 European initiatives that focus on improving sarcoma care
Initiative
The European Organisation for Research and Treatment of Cancer
(EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) develops and
coordinates studies on all aspects of sarcomas within the framework of the
EORTC. They have an extensive standardised clinical trial database used for
various other research projects. Currently, there are 54 member institutions
from 14 countries in the group [38].
European CanCer Organisation (ECCO) Essential Requirements for
Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma
(2017). They provide oncology teams, patients, policymakers and managers
an overview of the elements needed in any healthcare system to provide
high-quality care throughout the sarcoma patient’s journey [6].
Sarcoma PAtients EuroNet (SPAEN) policy paper: Sarcoma Patient
Pathway Analysis and recommendations for Service Development
(2016). This paper outlines what patients expect sarcoma treatment to look
like, how they expect services to be structured and developed to respond
to patient needs, and how referral practices should evolve internationally [7].
EURO EWING consortium – international clinical trials to improve
survival from Ewing sarcoma (EEC project) (2014–2018). This initiative is
coordinated by University College London and involves 20 European partners.
It is funded by the European Union’s Framework Programme 7 (FP7). It is a
coalition of clinical study groups to bring greater patient access to clinical
trials, promote sharing of knowledge and improve patient results [39].
euroSARC project. Funded by the European Union’s Framework Programme
7 (FP7), it aims to design, structure and implement European clinical trials on
rare sarcoma subtypes within an integrated translational study network [40].
Conticabase – European sarcoma database and tumour bank. The
database currently stores information on 16,689 sarcoma patients in Europe,
including tumour characteristics, treatment and follow-up, as well as tumour
samples [41].to EURACAN with implementation, in terms of oper-
ational solutions and professional guidance in quality of
care, epidemiology, research and innovation, and educa-
tion [35, 36].
Finally, Rare Cancers Europe (RCE) is leading policy
campaigns and actions on many of the key priority areas
identified in the Sarcoma Policy Checklist, including: im-
proving patients’ involvement in clinical trial design and
participation in clinical trials; standardising, capturing
and merging big data for research purposes; improving
access to rare cancer therapies; and improving education
on rare cancers [5, 37].
Although many of the above initiatives are still in the
conceptual or early phases of implementation, they may
have a marked impact on the landscape for sarcoma pa-
tients in years to come.
Conclusions
As demonstrated in this paper, there have been many
promising initiatives aiming to improve the care of sar-
coma patients in recent years. Yet gaps remain – par-
ticularly in Europe’s lesser-resourced countries – and we
must ensure all sarcoma patients have access to appro-
priate information, treatment and care. Patients and
their representatives should be included in the planning
and evaluation of sarcoma care. A multidisciplinaryLinks
http://www.eortc.org/research_field/soft-tissue-bone/
http://www.croh-online.com/article/S1040-8428(16)30361-4/fulltext
http://www.sarcoma-patients.eu/en/dings/19-spaen-policy-paper-on-
quality-care-in-sarcomas-now-available
http://www.euroewing.eu
http://eurosarc.eu/
https://conticabase.sarcomabcb.org/
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pert centres for sarcoma – and link with community
providers as well. National and European training pro-
grammes are needed to build specialised expertise in the
diagnosis and care of sarcomas for all healthcare profes-
sionals involved in sarcoma care. Both European- and
national-level collaborations are needed to achieve sus-
tainable and equitable solutions in all countries.
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